rituximab-abbs
The Case for Switching to Rituximab Biosimilar
Switching from originator rituximab to rituximab-abbs can save an institution up to $13,000 annually per patient ...
FEBRUARY 16, 2022
FDA Approves Truxima, First Biosimilar to Rituxan
The FDA approved rituximab-abbs (Truxima, Celltrion/Teva), the first biosimilar to rituximab (Rituxan, ...
DECEMBER 1, 2018
Load more